We live in a time of hope for millions around the world, as technological advancements and research breakthroughs hold the ...

Effective provider segmentation can make or break a new drug launch, and can also improve the lifecycle of existing portfolio ...

E. Magnus Ohman, vice president of global development, general medicine, Amgen, reflects on the remarkable evolution of North Carolina's biotechnology sector, tracing its growth from humble origins to ...

The brain cancer therapy recently approved by the FDA, Voranigo (vorasidenib), was developed from research by Duke University’s Darell Bigner and Johns Hopkins University's Bert Vogelstein and ...

In the 1980s, North Carolina emerged as a hub for biotechnology, largely due to the establishment of the North Carolina Biotechnology Center (NCBiotech). A state-supported, accelerator-style entity, ...

Biopharmaceutical companies must address the frictions and challenges that have quietly infiltrated the drug development ...

Conventional process liquid and buffer manufacturing is resource-intensive, requiring a significant facility footprint and high costs associated with labor, particularly as biologic drug production ...

The shift from traditional batch processes to intensified continuous processes is more than just a trend—it's the future of monoclonal antibody (mAb) production. Cytiva recognizes the need for more ...

Perfusion is a cell culture method becoming increasingly popular for producing monoclonal antibodies and their derivatives. It offers higher space-time yields (STY) and shorter residence time for ...

As AI integration increases across biopharmaceutical R&D functions, understanding model ambiguities with respect to AI ...